1 / 22

Pooled Analysis of Trials Comparing Titanium Nitride Oxide Coated Stents with Paclitaxel Eluting Stents in Patients Un

Pooled Analysis of Trials Comparing Titanium Nitride Oxide Coated Stents with Paclitaxel Eluting Stents in Patients Undergoing PCI. Otto M. Hess Swiss Cardiovascular Center University Hospital, Bern otto.hess @ insel.ch. Conflict of Interest Statement. Travel Support

kristin
Download Presentation

Pooled Analysis of Trials Comparing Titanium Nitride Oxide Coated Stents with Paclitaxel Eluting Stents in Patients Un

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Pooled Analysis of Trials Comparing Titanium Nitride Oxide Coated Stents with Paclitaxel Eluting Stents in Patients Undergoing PCI Otto M. Hess Swiss Cardiovascular Center University Hospital, Bern otto.hess @ insel.ch

  2. Conflict of Interest Statement Travel Support Biotronik AG, Baar Surcotec SA, Geneva Bioring SA, Geneva Biosteel GmbH, Aachen Hexacath SA, Paris Speed & Good AG, Ruggell Stent Technology AG, Zug CardioLab SA, Oberbüren

  3. LateLoss Camenzind E. et al. Circulation 115: 1440-55, 2007 Vascularhealing Inflammation

  4. Coverage of Overlapping Stents Baseline Cypher 2.25 x 23, 2.5 x 28, 3 x 33, 3x23 mm pre

  5. Cardiac Death Death MI MI or Death Stent Thrombosis TLR

  6. Cobalt-ChromiumStentInflammatoryGranuloma Magic Stent

  7. TITAN®- StentTitanium-Nitride-Oxide Coating TITAN-Coating (Titanium-Nitride-Oxide) Nitrogen, Oxygen and Titanium atoms are bound by electronic forces. (L. Pauling: classification)

  8. Titanium – The Material of Choice ? 10’000 100 1

  9. Titan Stent Titan Stent sputtered Bare metal stent No NO High NO High NO

  10. 1607 pts undergoing PCI withTiNOX, SES or PES 542 pts received SES 558 pts received TiNOX Propensity score matching 389 pts matched 389 pts matched The SIRTAX II Registry 507 pts received PES 389 pts matched

  11. Baseline characteristics before propensity score matching

  12. Baseline characteristics after propensity score matching

  13. Histogram of Propensity Scores • Kernel-Density and Threshold for Common Support

  14. MACE (death, MI or TVR) p = 1.00 p = 0.78 Titan vs. Paclitaxel Titan vs. Sirolimus

  15. Death Titan vs. Sirolimus Titan vs. Paclitaxel p = 0.79 p = 0.89

  16. Target Lesion Revascularization Titan vs. Paclitaxel Titan vs. Sirolimus p = 1.00 p = 0.88

  17. Target Vessel Revascularization Titan vs. Paclitaxel Titan vs. Sirolimus p = 0.90 p = 0.41

  18. Myocardial Infarction Titan vs. Paclitaxel Titan vs. Sirolimus p = 0.24 p = 0.21

  19. Clinical outcome in the propensity-score-matched groups

  20. Conclusions Titanium-coated stents show a similar safety and efficiency as DES of the first generation over 3 years suggesting no benefit of first generation drug eluting stents over Titanium-coated stents Stent thrombosis rates are low for all 3 stent types but are lowest for Titanium-coated stents. However, dual antiplatelet therapy was carried out only for 3 months in Titanium-coated and 12 months in drug-eluting stents Thus, bio-active stents are a true alternative to DES of the first generation specifically in patients with an increased bleeding risk and in elderly.

  21. Forever young

More Related